- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06084221
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems (FORTRESS)
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems (FORTRESS)
This project seeks to address the overdose epidemic by working with overdose fatality review (OFR) teams. Current OFR practices rely on a case review model where OFR teams assess one or two overdose cases to make policy and program recommendations. However, the continued rise in overdose rates and number of preventable overdose deaths suggest a need to shift OFR teams away from case review and toward using timely population-level data to better inform their recommendations and actions.
The goal of this project, Fatal Overdose Review Teams - Research to Enhance Surveillance Systems (FORTRESS), is to improve standard OFR practices by equipping OFRs with a data dashboard built on near real-time aggregate data, linked across multiple sources and presented in a way that helps identify common "overdose touchpoints," or opportunities to connect individuals at risk for overdose with evidence-based treatment.
During the first project phase, the FORTRESS team will design the "Overdose Touchpoints Dashboard'' (Aim 1). The FORTRESS team will also train OFR team members in "Data-Driven Decision Making" (DDDM) to effectively use the dashboard. The FORTRESS team also includes individuals involved in developing the CDC's OFR best practice guidelines and a pilot study of OFR adherence to these guidelines, which will inform the FORTRESS team's development of an "OFR Fidelity Tool'' (Aim 2). This tool will be the first of its kind.
For the second project phase, the FORTRESS team will conduct a cluster-randomized stepped-wedge trial comparing the impact of the intervention (dashboard + DDDM training) versus standard OFR practices on both implementation (Aim 3) and effectiveness outcomes (Aim 4). Implementation outcomes include implementation process fidelity (Stages of Implementation Completion), staff acceptance of harm reduction philosophies (qualitative interviews), OFR fidelity to CDC best practices (FORTRESS OFR Fidelity Tool), and usability of the Overdose Touchpoint Dashboard, (Systems Usability Scale). A statewide OFR data repository serves as a rich source of data on effectiveness outcomes, including OFR team recommendation quality and local actions to implement recommended overdose prevention strategies. The FORTRESS team will also survey OFR team members to assess changes in their attitudes toward evidence-based overdose prevention strategies. In sum, the FORTRESS team is uniquely qualified to help OFRs use more comprehensive available data to inform quality, action-oriented recommendations to reduce overdose. Funding for this project comes from the HEAL Initiative (https://heal.nih.gov/).
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria for FORTRESS staff personnel recruited to complete surveys, focus groups and/or interviews:
- 1) member of local overdose fatality review (OFR) team; OR 2) local county leader of organizations represented by OFR (OFR facilitator, public jail administrators, chief of police, judge, addiction treatment CEO/CFO, public health director, etc.).
Inclusion criteria for FORTRESS administrative data:
- all residents of Indiana that have experienced fatal and/or non-fatal overdose as identified by administrative data sources.
Exclusion Criteria
- N/A
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: OFR Team Practice as Usual
Data are collected regarding standard OFR Team practice and outcomes before implementation of the FORTRESS Intervention
|
|
|
Experimental: FORTRESS
Participating counties receive both training in data-driven decision making and inventory of overdose-prevention strategies
|
The intervention consists of providing real-time data on overdose touchpoints to OFRs and training in DDDM for continuous quality improvement cycles, leading to improved OFR recommendations and implementation of overdose prevention strategies.
A list of overdose prevention and harm reduction strategies will be provided to OFRs for possible implementation, depending on local needs and final dashboard development.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Organizational readiness to implement change
Time Frame: Months 18, 24, 30, 36, 42, 48, 54, & 60
|
12-items that assess perceived readiness to implement new innovations that will be administered to 15 OFR team members and 5 system leaders per each of 18 counties.
|
Months 18, 24, 30, 36, 42, 48, 54, & 60
|
|
Cultural Exchange Inventory (adapted to evaluate OFR team alliance)
Time Frame: Months 18, 24, 30, 36, 42, 48, 54, & 60
|
15-items that measure knowledge and attitudes between organizations that will be administered to 15 OFR team members and 5 system leaders per each of 18 counties.
|
Months 18, 24, 30, 36, 42, 48, 54, & 60
|
|
Harm reduction acceptability scale
Time Frame: Months 18, 24, 30, 36, 42, 48, 54, & 60
|
25-items that measures the adoption of a harm reduction approach in responding to people who use substances that will be administered to 15 OFR team members and 5 system leaders per each of 18 counties.
|
Months 18, 24, 30, 36, 42, 48, 54, & 60
|
|
Systems Usability Scale
Time Frame: Months 18, 24, 30, 36, 42, 48, 54, & 60
|
10-items that assesses the usability of dashboard for OFRs that will be administered to 15 OFR team members and 5 system leaders per each of 18 counties.
|
Months 18, 24, 30, 36, 42, 48, 54, & 60
|
|
Stages of Implementation Completion (SIC)
Time Frame: Baseline through study completion, an average of 5 years
|
The SIC is a measure of implementation process fidelity and allows for continuous measurement of implementation success.
The SIC is an observation-based assessment tool that qualitatively measures intervention implementation process and fidelity.
Assessment of the SIC results will be ongoing across the intervention time period and into sustainment.
|
Baseline through study completion, an average of 5 years
|
|
OFR Fidelity Tool
Time Frame: Months 18-54
|
To be developed fidelity assessment tool that will be completed by each OFR facilitator after a monthly meeting.
|
Months 18-54
|
|
Dashboard Aggregate Usage
Time Frame: Months 14-54
|
Web Cookies and anonymized IDs for each unique user to track dashboard usage that will be tracked on an on-going basis.
Dr. Reda will review results monthly.
|
Months 14-54
|
|
Organization's implementation climate (adapted to evaluate overdose prevention strategies)
Time Frame: Months 18, 24, 30, 36, 42, 48, 54, & 60
|
18-items that assesses the degree to which the climate is supportive of adopting new innovations that will be administered to 15 OFR team members and 5 system leaders per each of 18 counties.
|
Months 18, 24, 30, 36, 42, 48, 54, & 60
|
|
Quality OFR Recommendations
Time Frame: Months 14-54
|
OFR team recommendations will be gathered monthly.
We will be coding the quality of OFR team recommendations using the coding system that we developed in phase 1 of our FORTRESS project.
This measure involves qualitative assessments of whether a recommendation meets certain standards of quality.
The qualitative coding will be conducted by research staff in a digital spreadsheet.
|
Months 14-54
|
|
Uptake of OFR Interventions
Time Frame: Months 14-54
|
OFR team recommendations will be gathered monthly.
Uptake of an intervention will be defined as implementation of the recommendation.
OFR team overdose prevention recommendations will be coded for uptake (whether or not they were implemented).
This measure involves quantitative assessment of the incidence of uptake.
|
Months 14-54
|
|
Overdose
Time Frame: Month 35-40 (interim) and month 53-57 (final)
|
Mortality data is collected via death certificates that are submitted by county coroners to the IDOH Division of Vital Records, which include information on underlying cause of Death.
Data will include all fatal accidental drug overdose deaths (X40-X44).
|
Month 35-40 (interim) and month 53-57 (final)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthew C Aalsma, PhD, Indiana University School of Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15922
- 1R61DA057660-01 (U.S. NIH Grant/Contract)
- 4R33DA057660-02 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance-Related Disorders
-
University of Wisconsin, MadisonNational Institute on Drug Abuse (NIDA); Rush University Medical CenterCompletedSubstance-Related Disorders | Substance Use | Substance AbuseUnited States
-
New York State Psychiatric InstituteNational Institute on Drug Abuse (NIDA)CompletedSubstance-Related Disorders | Substance Use | Substance Use Disorders | Substance Abuse | Substance Dependence | Substance Related Problem
-
VA Office of Research and DevelopmentActive, not recruiting
-
National Institute on Drug Abuse (NIDA)CompletedSubstance-related Disorders
-
US Department of Veterans AffairsCompletedAlcoholism | Substance Use Disorders | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
Norwegian University of Science and TechnologyCompletedSubstance-related DisordersNorway
-
University Hospital, Basel, SwitzerlandPsychiatric Hospital of the University of BaselCompleted
-
University of LuebeckFederal Ministry of Health, GermanyCompletedSubstance-related Disorders
-
University of Illinois at Urbana-ChampaignCompletedSubstance-related Disorders
-
University of NebraskaCompletedSubstance-related Disorders | Alcohol-related DisordersUnited States
Clinical Trials on Data-Driven Decision Making (DDDM)
-
University of MichiganCompleted
-
The University of Texas Health Science Center,...TerminatedPregnancy Related | Elective InductionUnited States
-
Mahidol UniversityUniversity of Medical Technology, YangonCompletedCognitive ChangeMyanmar
-
German Institute of Human NutritionCharite University, Berlin, Germany; Freie Universität Berlin; German Center...CompletedQuality of Life | Stress, Psychological | BehaviorGermany
-
Taipei Medical University Shuang Ho HospitalCompleted
-
University of AarhusTrygFonden, DenmarkCompletedCardiovascular Disease | High Cholesterol
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH)Completed
-
Duke UniversityNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...CompletedNeonatal Critical Illness | Pediatric Critical IllnessUnited States
-
Christiana Care Health ServicesNational Institute of General Medical Sciences (NIGMS); Thomas Jefferson University and other collaboratorsCompleted
-
Massachusetts General HospitalObsessive Compulsive FoundationCompletedObsessive-Compulsive DisorderUnited States